Ketogenic Diet May Slow Glioblastoma Progression, New Study Reveals

Case Study: A Unique Approach to Glioblastoma Management

Patient Background

Five years ago, a 26-year-old man was diagnosed with glioblastoma, a type of brain cancer known for its low recovery rates. Remarkably, he now leads an active and high-quality life with minimal tumor progression, despite opting out of conventional treatment options. Researchers suggest that his strict adherence to a ketogenic diet may have played a significant role in slowing the progression of his glioblastoma.

Understanding Glioblastoma

Glioblastoma is a severe form of brain cancer that claims around 15,000 lives each year. Standard treatment protocols, which include surgical intervention, radiotherapy, and chemotherapy, yield a survival rate of only 5-13% for those who live beyond five years. Additionally, some patients are prescribed corticosteroids to manage edema and bevacizumab to control angiogenesis.

Choosing the Ketogenic Diet

In 2014, the patient, diagnosed with IDH1-mutant glioblastoma, made the choice to refuse standard care. Instead, he adopted ketogenic metabolic therapy (KMT), which emphasizes a low-carbohydrate, high-fat diet primarily composed of saturated fats, meats, and select vegetables. His commitment to this diet was strong, as he regularly monitored his blood glucose levels through the glucose/ketone index, maintaining an average index of around 2.0 throughout his treatment.

Tumor Progression Observations

Three years post-diagnosis, medical professionals noted a gradual tumor growth during his initial treatment at University Hospitals Plymouth NHS Trust in the UK. In 2017, he opted for surgical intervention to remove part of the tumor. However, after the surgery, he increased his carbohydrate intake, which led to more advanced tumor progression as revealed by an MRI in 2018. The patient then returned to a strict ketogenic diet and has maintained it since. Doctors have observed minimal vasogenic edema and relatively slow tumor growth. As of April 2021, he is 82 months post-diagnosis and enjoys a good quality of life.

The Role of the Ketogenic Diet in Tumor Metabolism

Glioblastoma, like many aggressive cancers, primarily derives its energy from glucose through a process called glycolysis. By implementing a low-carbohydrate, high-fat diet, the patient limited glucose availability to the tumor, potentially disrupting pathways associated with tumor growth. This dietary shift induces a state of ketogenesis, producing ketone bodies that can serve as an alternative energy source, reducing reliance on glucose.

The patient’s IDH1-mutant glioblastoma may have contributed to his extended survival, with studies indicating that individuals with this mutation typically live longer than those without, averaging 31 months compared to 15 months. Professor Thomas Seyfried of Boston College, a co-author of the study, expressed surprise at how KMT could synergize with the IDH1 mutation, targeting the two primary metabolic pathways essential for glioblastoma growth.

Future Research Directions

While the patient’s experience extends beyond 80 months following his diagnosis, the findings of this case study do not definitively establish a causal relationship between the ketogenic diet and slowed tumor progression. Further clinical trials are necessary to evaluate the effectiveness of this dietary approach across various glioblastoma cases, particularly for those without the IDH1 mutation. The co-authors caution that patients lacking this mutation might require additional treatments, such as glutamine-targeting drugs, in conjunction with a ketogenic diet to effectively manage tumor growth.

Although this case report represents just one patient’s journey, it opens avenues for future research into the potential benefits of ketogenic diets in glioblastoma and possibly other cancers.

References

1. Hayward, E. (2021). Case study shows patient on ketogenic diet living fully with IDH1-mutant glioblastoma. EurekAlert! Accessed on June 14, 2021. Retrieved from https://www.eurekalert.org/pub_releases/2021-06/bc-css061021.php.
2. Park, C. et al. (2020). Long-term survivors of glioblastoma are a unique group of patients lacking universal characteristic features. Neuro-Oncology Advances; 2(1): January-December 2020, vdz056. Doi: 10.1093/noajnl/vdz056.
3. Seyfried, T. et al. (2021). Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report. Frontiers in Nutrition. Doi: 10.3389/fnut.2021.682243.
4. Calvert, A.E. et al. (2017). Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Reports; 19(9): 1858-1873. Doi: 10.1016/j.celrep.2017.05.014.